Search Results

You searched for : LatestAstrazenecaNews  

Status on FDA Advisory Committee vote on roxadustat in anaemia of chronic kidney disease

New solutions are needed for the six million people in the US affected by anaemia of chronic kidney disease....
Jul 17

Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

...
Jun 24

Orpathys approved in China for patients with lung cancer and MET gene alterations

This approval follows a priority review designation by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) and marks the first ...
Jun 23

Koselugo approved in the EU for children with neurofibromatosis type 1 and plexiform neurofibromas

First medicine approved in the EU to treat this rare and debilitating genetic condition...
Jun 22

AstraZeneca welcomes Court ruling on supply of its COVID-19 vaccine to Europe

In fewer than twelve months, AstraZeneca has worked extremely hard to develop an effective vaccine at no profit and is the second-largest supplier to ...
Jun 18

COVID-19 Vaccine AstraZeneca effective against Delta (‘Indian’) variant

Real-world data demonstrated 92% vaccine effectiveness against hospitalisations due to the Delta variant ...
Jun 16

Serum Institute of India obtains emergency use authorisation in India for AstraZeneca’s COVID-19 vaccine

AstraZeneca’s COVID-19 vaccine has been granted emergency use authorization in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for ...
Jan 07

Farxiga granted Priority Review in the US for the treatment of patients with chronic kidney disease

Farxiga could become the first SGLT2 inhibitor approved to treat patients with chronic kidney disease, with and without type-2 diabetes...
Jan 06

Update on SOURCE Phase III trial for tezepelumab in patients with severe, oral corticosteroid-dependent asthma

Tezepelumab’s effect on other efficacy parameters was similar to those observed in previous trials, including the registrational Phase III NAVIGATOR trial....
Dec 22

Tagrisso approved in the US for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

Approval based on unprecedented results from the ADAURA Phase III trial where Tagrisso reduced the risk of disease recurrence or death by 80%...
Dec 21

Imfinzi recommended for approval in the EU by CHMP for non-small cell lung cancer

This new dosing option is consistent with the approved Imfinzi dosing in extensive-stage small cell lung cancer and once approved, will be available to ...
Dec 15

Trixeo Aerosphere approved in the EU for maintenance treatment of COPD

COPD is a progressive disease, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness and is the third leading ...
Dec 14

Trastuzumab deruxtecan recommended for approval in the EU by CHMP for HER2-positive metastatic breast cancer

The impact of the disease is significant, with breast cancer responsible for more than 137,000 deaths per year....
Dec 14

Enhertu continues to demonstrate durable responses with new data from DESTINY-Breast01 in HER2

Enhertu continued to demonstrate impressive efficacy and durable responses in patients with HER2-positive metastatic breast cancer following two or more prior HER2-based regimens....
Dec 10

AZD1222 Oxford Phase III trials interim analysis results published in The Lancet

Interim analysis showed vaccine is effective at preventing COVID-19, with no severe cases and no hospitalizations more than 21 days after first injection...
Dec 09

Calquence data across four trials reinforces cardiovascular safety profile for chronic lymphocytic leukaemia

...
Dec 08

Calquence shows long-term efficacy and tolerability at three years for refractory mantle cell lymphoma

Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with Calquence (acalabrutinib) remained progression-free for a median of 22 months....
Dec 07

Crestor to be divested to Grünenthal in Europe

AstraZeneca has agreed to sell the rights to Crestor and associated medicines in over 30 countries in Europe, except the UK and Spain....
Dec 01

Lokelma label update approved in China for patients with hyperkalaemia on chronic haemodialysis

The NMPA has approved a dosing label update in China for AstraZeneca’s Lokelma to include patients with hyperkalaemia on chronic haemodialysis....
Nov 25

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in ...
Nov 23

Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19

CALAVI did not meet the primary endpoint of increasing the proportion of patients who remained alive and free of respiratory failure...
Nov 12

Tezepelumab NAVIGATOR Phase III trial met primary endpoint of a statistically significant and clinically meaningful reduction in exacerbations in a broad population of patients with severe asthma

AstraZeneca and Amgen today announced positive results from the new medicine tezepelumab in patients with severe, uncontrolled asthma....
Nov 10

Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia

Calquence demonstrated superior progression-free survival and favorable tolerability in both previously untreated and relapsed or refractory patients...
Nov 09

Brilinta approved in the US to reduce the risk of stroke in patients with an acute ischaemic stroke or high-risk transient ischaemic attack

New indication expands use of Brilinta beyond the cardiovascular disease to patients with mild-to-moderate stroke...
Nov 06

Lynparza approved in the EU as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

Lynparza in combination with bevacizumab demonstrated as a treatment for the treatment of HRD-positive advanced Ovarian Cancer...
Nov 05

25 Matching result(s) found!

-Advertisements-




Trending Now

Scars That Never Heal: The Painful Reality of Female Genital MutilationFebruary 06, 2025
Maharashtra’s Healthcare Betrayal: Why Are Crucial Funds Going Unused?February 06, 2025
1vision, 1 mission: Avaada Foundation’s CSR initiatives are powering communities and delivering sustainable progress across 5 key focus areasFebruary 06, 2025
Top 5 Technology Brands that are Transforming the Cancer Care Journeys for Hospitals and PatientsFebruary 06, 2025
Women's Wellness brand NUA Raises Rs 35 Crore in Pre-Series C led by Mirabilis Investment TrustFebruary 06, 2025
8 Effective Ways to Minimize Postpartum ComplicationsFebruary 06, 2025
Does Where You Live Decide Your Fate? The Urban-Rural Breast Cancer Divide in IndiaFebruary 06, 2025
Nepal leads the world with largest pictorial health warnings on all tobacco productsFebruary 05, 2025
Fleetguard Filters Private Limited Recognized for Excellence in CSR at Navabharat’s 4th CSR ConclaveFebruary 05, 2025
Six new regions of the Russian Federation are set to connect to Moscow's AI medical services platform, MosMedAIFebruary 04, 2025
Six new regions of the Russian Federation are set to connect to Moscow's AI medical services platform, MosMedAIFebruary 04, 2025
Ashok Leyland Reinforces ESG Commitment, Ranked No. 1 Globally in Sustainalytics’ RatingsFebruary 04, 2025
Calcium Supplements: Do You Really Need Them?February 04, 2025
Digital Diagnostics Doubles Its Foreign Publication Count in 2024February 04, 2025
World Cancer Day quotesFebruary 04, 2025
India can take a big leap in Cancer Care with Improved access to treatment and People-centered Approach: ExpertsFebruary 04, 2025
Lilly India appoints Winselow Tucker as the President and General ManagerFebruary 04, 2025
Driving Excellence in Clinical Research: ISCR's 18th Annual Conference Highlights Innovation, Technology, and Patient-CentricityFebruary 04, 2025
Southern Cross University introduces Access25 initiative to make international education more accessible to Indian studentsFebruary 04, 2025
Why Millions Suffer from Ineffective Treatments And the New Science That Can Save ThemFebruary 04, 2025